NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
| 19.02 | |
| 19.36 | |
| - | |
| 19.36 | |
| 17.85 | |
| 10.87-35.1 | |
| 1 960 M | |
| 108 M | |
| 550 M | |
| -0.31 | |
| 0.694 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago. These figures are adjuste...
ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $33.4 million in its second quarter. The St. Helier, Jersey-based company said it had a los...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
